Results of induction therapy
Patients . | No. patients . | CR, no. (%, 95% CI) . | Median time to CR, d (range) . |
|---|---|---|---|
| All | 44 | 39 (89, 75-96) | 28 (19-48) |
| Low risk | 25 | 24 (96, 80-100) | 28 (19-48) |
| High risk | 19 | 15* (79, 54-94) | 32 (22-41) |
Patients . | No. patients . | CR, no. (%, 95% CI) . | Median time to CR, d (range) . |
|---|---|---|---|
| All | 44 | 39 (89, 75-96) | 28 (19-48) |
| Low risk | 25 | 24 (96, 80-100) | 28 (19-48) |
| High risk | 19 | 15* (79, 54-94) | 32 (22-41) |
Low risk was defined as having an initial WBC count below 10 × 109/L; high risk, as having an initial WBC count above 10 × 109/L. The low-risk patient who failed did so within 2 days of the start of therapy; the 4 high-risk patients, within 2, 2, 3, and 17 days of therapy.
Eleven of 15 patients with GO, 2 of 2 patients with GO + idarubicin, 1 of 1 patient with idarubicin, and 1 of 1 patient with only ATRA + ATO.